Coeptis Therapeutics Holdings (COEP) Income Statement: Revenue & Earnings

Coeptis Therapeutics Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Coeptis Therapeutics Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.08	0.03
Cost of Revenue	1.04	0.00	0.00	0.00	0.96
Gross Profit	-1.04	0.00	0.00	0.08	-0.93
Operating Expenses
Research & Development	2.33	6.67	0.02	0.00	0.00
Selling, General & Administrative	6.68	13.35	34.18	14.12	5.78
Operating Expenses	9.02	21.49	34.20	14.12	5.78
Operating Income	-10.05	-21.49	-34.20	-14.05	-6.71
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.40	-0.11	0.22	0.19	-0.15
Other Income/Expense	-0.82	0.33	-3.16	0.78	-2.29
Income
Income Before Tax	-10.88	-21.27	-37.57	-13.45	-9.16
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-10.88	-21.27	-37.57	-13.45	-9.16
Net Income - Continuous Operations	-10.88	-21.27	-37.57	-13.45	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-9.44	-20.49	-36.35	-12.81	-6.39
EBIT	-10.05	-21.49	-37.36	-13.26	-6.71
Depreciation & Amortization	1.04	1.00	1.00	0.45	0.32
Earnings Per Share
Basic EPS	-6.00	-17.00	-53.00	-13.00	-30.00
Diluted EPS	-6.00	-17.00	-53.00	-13.00	-30.00
Basic Shares Outstanding	1.93	1.28	0.71	1.02	0.30
Diluted Shares Outstanding	1.93	1.28	0.71	1.02	0.30